Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Esophageal Neoplasms | 4 | 2023 | 1658 | 1.570 |
Why?
|
Data Interpretation, Statistical | 10 | 2024 | 2691 | 1.550 |
Why?
|
Proportional Hazards Models | 15 | 2022 | 12467 | 1.450 |
Why?
|
Survival Analysis | 14 | 2022 | 10083 | 1.420 |
Why?
|
Trifluridine | 2 | 2019 | 28 | 1.240 |
Why?
|
Randomized Controlled Trials as Topic | 17 | 2024 | 10213 | 1.210 |
Why?
|
Hyperthermia, Induced | 2 | 2023 | 417 | 1.170 |
Why?
|
Medical Oncology | 5 | 2023 | 2316 | 1.150 |
Why?
|
Breast Neoplasms | 14 | 2024 | 20981 | 1.150 |
Why?
|
Neoadjuvant Therapy | 5 | 2022 | 2827 | 1.130 |
Why?
|
Rectal Neoplasms | 3 | 2021 | 1156 | 1.080 |
Why?
|
Stomach Neoplasms | 3 | 2021 | 1458 | 1.040 |
Why?
|
Esophagectomy | 3 | 2023 | 469 | 0.920 |
Why?
|
Lung Neoplasms | 9 | 2022 | 13382 | 0.880 |
Why?
|
Esthesioneuroblastoma, Olfactory | 1 | 2024 | 58 | 0.880 |
Why?
|
Oxadiazoles | 2 | 2020 | 94 | 0.860 |
Why?
|
Muscular Dystrophy, Duchenne | 3 | 2021 | 265 | 0.860 |
Why?
|
Clinical Trials as Topic | 4 | 2021 | 8000 | 0.840 |
Why?
|
Drug-Eluting Stents | 2 | 2019 | 681 | 0.840 |
Why?
|
Cardiovascular Diseases | 12 | 2023 | 15513 | 0.830 |
Why?
|
Humans | 135 | 2024 | 761098 | 0.820 |
Why?
|
Research Design | 7 | 2024 | 6178 | 0.810 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 6 | 2022 | 5318 | 0.810 |
Why?
|
Nose Neoplasms | 1 | 2024 | 249 | 0.760 |
Why?
|
Immunotherapy | 6 | 2024 | 4642 | 0.750 |
Why?
|
Kaplan-Meier Estimate | 5 | 2018 | 6482 | 0.740 |
Why?
|
Neoplasms | 10 | 2022 | 22125 | 0.740 |
Why?
|
Treatment Outcome | 28 | 2024 | 64670 | 0.730 |
Why?
|
Survival Rate | 10 | 2021 | 12727 | 0.700 |
Why?
|
Aromatase | 1 | 2020 | 147 | 0.670 |
Why?
|
Colonic Neoplasms | 2 | 2023 | 2528 | 0.660 |
Why?
|
Adenocarcinoma | 3 | 2023 | 6340 | 0.630 |
Why?
|
Head and Neck Neoplasms | 2 | 2024 | 2896 | 0.590 |
Why?
|
Paclitaxel | 3 | 2023 | 1730 | 0.580 |
Why?
|
Propanolamines | 1 | 2018 | 163 | 0.580 |
Why?
|
Rifampin | 1 | 2019 | 338 | 0.570 |
Why?
|
Aspirin | 3 | 2024 | 3128 | 0.570 |
Why?
|
Patient Care Management | 1 | 2020 | 302 | 0.560 |
Why?
|
Adrenergic beta-Antagonists | 3 | 2018 | 1242 | 0.560 |
Why?
|
Epoetin Alfa | 1 | 2016 | 78 | 0.550 |
Why?
|
Blood Pressure Determination | 2 | 2023 | 633 | 0.540 |
Why?
|
Gonadotropin-Releasing Hormone | 1 | 2022 | 1146 | 0.530 |
Why?
|
Lymph Node Excision | 2 | 2023 | 1269 | 0.530 |
Why?
|
Taxoids | 2 | 2018 | 668 | 0.520 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2024 | 4021 | 0.520 |
Why?
|
Anticholesteremic Agents | 2 | 2020 | 968 | 0.500 |
Why?
|
Digestive System Surgical Procedures | 1 | 2021 | 571 | 0.500 |
Why?
|
Hypertension | 5 | 2023 | 8537 | 0.500 |
Why?
|
Therapeutics | 1 | 2015 | 113 | 0.500 |
Why?
|
Axilla | 1 | 2018 | 624 | 0.490 |
Why?
|
Endpoint Determination | 4 | 2024 | 590 | 0.490 |
Why?
|
Comparative Effectiveness Research | 1 | 2020 | 709 | 0.480 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 11 | 2024 | 11732 | 0.470 |
Why?
|
Prostatic Neoplasms | 4 | 2022 | 11103 | 0.460 |
Why?
|
Urologic Neoplasms | 1 | 2017 | 314 | 0.440 |
Why?
|
Polydeoxyribonucleotides | 2 | 2024 | 136 | 0.430 |
Why?
|
Statistics as Topic | 3 | 2020 | 2359 | 0.430 |
Why?
|
Receptor, erbB-2 | 5 | 2024 | 2553 | 0.430 |
Why?
|
Confidence Intervals | 3 | 2020 | 2927 | 0.420 |
Why?
|
Standard of Care | 1 | 2016 | 550 | 0.410 |
Why?
|
Coronavirus Infections | 2 | 2020 | 3094 | 0.410 |
Why?
|
Pneumonia, Viral | 2 | 2020 | 3216 | 0.400 |
Why?
|
Vascular Diseases | 1 | 2020 | 1160 | 0.400 |
Why?
|
Drug Therapy | 1 | 2015 | 503 | 0.400 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2024 | 2293 | 0.380 |
Why?
|
Carcinoma, Renal Cell | 2 | 2024 | 3163 | 0.370 |
Why?
|
Clinical Trials, Phase III as Topic | 5 | 2024 | 858 | 0.370 |
Why?
|
Decision Support Techniques | 1 | 2021 | 2000 | 0.370 |
Why?
|
Colorectal Neoplasms | 3 | 2020 | 6919 | 0.370 |
Why?
|
Neoplasms, Second Primary | 1 | 2019 | 1051 | 0.360 |
Why?
|
Longitudinal Studies | 4 | 2024 | 14607 | 0.360 |
Why?
|
Chemotherapy, Adjuvant | 4 | 2024 | 3512 | 0.360 |
Why?
|
Statistical Distributions | 1 | 2010 | 63 | 0.360 |
Why?
|
Bone Density Conservation Agents | 1 | 2018 | 795 | 0.360 |
Why?
|
Quinolines | 1 | 2016 | 764 | 0.360 |
Why?
|
Biometry | 2 | 2010 | 563 | 0.350 |
Why?
|
Pandemics | 2 | 2020 | 8663 | 0.350 |
Why?
|
Acute Kidney Injury | 1 | 2022 | 1923 | 0.340 |
Why?
|
Soft Tissue Neoplasms | 1 | 2019 | 1158 | 0.340 |
Why?
|
Kidney Neoplasms | 2 | 2024 | 4251 | 0.330 |
Why?
|
Melanoma | 2 | 2018 | 5694 | 0.330 |
Why?
|
Antihypertensive Agents | 5 | 2023 | 2019 | 0.320 |
Why?
|
Carcinoma | 1 | 2020 | 2328 | 0.320 |
Why?
|
Consensus | 1 | 2018 | 3133 | 0.320 |
Why?
|
Adiposity | 1 | 2019 | 1879 | 0.310 |
Why?
|
Thymine | 2 | 2019 | 68 | 0.310 |
Why?
|
Skin Neoplasms | 2 | 2018 | 5809 | 0.310 |
Why?
|
Liver Neoplasms | 1 | 2024 | 4308 | 0.300 |
Why?
|
Dementia | 2 | 2021 | 2682 | 0.300 |
Why?
|
Multicenter Studies as Topic | 3 | 2024 | 1702 | 0.300 |
Why?
|
Heart Failure | 7 | 2024 | 11701 | 0.290 |
Why?
|
Thiazolidinediones | 1 | 2011 | 460 | 0.290 |
Why?
|
Aminopyridines | 2 | 2022 | 573 | 0.290 |
Why?
|
Sarcoma | 1 | 2019 | 1800 | 0.290 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2023 | 3609 | 0.290 |
Why?
|
Laparoscopy | 1 | 2019 | 2030 | 0.280 |
Why?
|
MicroRNAs | 1 | 2023 | 3758 | 0.280 |
Why?
|
Sample Size | 3 | 2015 | 841 | 0.280 |
Why?
|
Acute Coronary Syndrome | 1 | 2020 | 2191 | 0.280 |
Why?
|
Tuberculosis | 1 | 2019 | 2015 | 0.270 |
Why?
|
Pyrrolidines | 2 | 2019 | 339 | 0.270 |
Why?
|
Benzimidazoles | 2 | 2022 | 858 | 0.260 |
Why?
|
Ovarian Neoplasms | 1 | 2023 | 4853 | 0.260 |
Why?
|
Venous Thromboembolism | 1 | 2019 | 1868 | 0.260 |
Why?
|
Multiple Myeloma | 2 | 2024 | 5145 | 0.240 |
Why?
|
Time Factors | 10 | 2024 | 39953 | 0.240 |
Why?
|
Disease-Free Survival | 3 | 2024 | 6817 | 0.240 |
Why?
|
Area Under Curve | 2 | 2018 | 1636 | 0.230 |
Why?
|
Platelet Aggregation Inhibitors | 3 | 2020 | 2746 | 0.220 |
Why?
|
Patient Selection | 1 | 2015 | 4245 | 0.220 |
Why?
|
Antineoplastic Agents | 4 | 2024 | 13630 | 0.220 |
Why?
|
Hypoglycemic Agents | 2 | 2019 | 3086 | 0.220 |
Why?
|
Brain Neoplasms | 1 | 2024 | 9025 | 0.210 |
Why?
|
Drug Combinations | 2 | 2019 | 2048 | 0.200 |
Why?
|
Female | 29 | 2024 | 392458 | 0.190 |
Why?
|
Nasal Cavity | 1 | 2024 | 304 | 0.190 |
Why?
|
Pancreatic Neoplasms | 1 | 2019 | 5366 | 0.190 |
Why?
|
Myocardial Infarction | 4 | 2021 | 11475 | 0.190 |
Why?
|
Models, Statistical | 6 | 2024 | 5077 | 0.190 |
Why?
|
Cause of Death | 2 | 2019 | 3688 | 0.190 |
Why?
|
Double-Blind Method | 5 | 2019 | 12341 | 0.180 |
Why?
|
Prostate-Specific Antigen | 2 | 2022 | 2465 | 0.180 |
Why?
|
Phenylthiohydantoin | 1 | 2022 | 205 | 0.180 |
Why?
|
Risk Assessment | 5 | 2019 | 24013 | 0.180 |
Why?
|
Liver Cirrhosis, Biliary | 2 | 2012 | 108 | 0.180 |
Why?
|
Neoplasm Staging | 3 | 2024 | 11118 | 0.180 |
Why?
|
Models, Theoretical | 1 | 2012 | 3568 | 0.180 |
Why?
|
Neoplasm Recurrence, Local | 3 | 2024 | 9278 | 0.180 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2018 | 5667 | 0.170 |
Why?
|
Placebos | 1 | 2024 | 1666 | 0.170 |
Why?
|
Nasopharyngeal Neoplasms | 1 | 2023 | 290 | 0.170 |
Why?
|
Stroke | 1 | 2022 | 9720 | 0.170 |
Why?
|
Fallopian Tubes | 1 | 2020 | 178 | 0.170 |
Why?
|
Coronary Artery Disease | 1 | 2019 | 6504 | 0.170 |
Why?
|
Lymph Nodes | 2 | 2023 | 3461 | 0.170 |
Why?
|
Piperazines | 2 | 2021 | 2522 | 0.160 |
Why?
|
Bryostatins | 1 | 2019 | 24 | 0.160 |
Why?
|
Intermittent Pneumatic Compression Devices | 1 | 2019 | 28 | 0.160 |
Why?
|
Eosinophils | 1 | 2024 | 951 | 0.160 |
Why?
|
Codon, Nonsense | 1 | 2020 | 284 | 0.160 |
Why?
|
Antibodies, Monoclonal | 1 | 2016 | 9185 | 0.160 |
Why?
|
Ventilators, Mechanical | 1 | 2021 | 288 | 0.160 |
Why?
|
Blood Pressure | 4 | 2023 | 8478 | 0.160 |
Why?
|
Adenosine Monophosphate | 1 | 2020 | 231 | 0.160 |
Why?
|
Hormones | 1 | 2022 | 869 | 0.150 |
Why?
|
Phthalazines | 1 | 2021 | 383 | 0.150 |
Why?
|
Immunization, Passive | 1 | 2020 | 617 | 0.150 |
Why?
|
Isoniazid | 1 | 2019 | 283 | 0.150 |
Why?
|
Alanine | 1 | 2020 | 608 | 0.140 |
Why?
|
Cisplatin | 1 | 2023 | 1651 | 0.140 |
Why?
|
Asthma | 1 | 2016 | 6229 | 0.140 |
Why?
|
Simvastatin | 1 | 2020 | 346 | 0.140 |
Why?
|
Anastomosis, Surgical | 1 | 2021 | 982 | 0.140 |
Why?
|
Intensive Care Units | 2 | 2021 | 3743 | 0.140 |
Why?
|
Neoplasm Invasiveness | 2 | 2024 | 3591 | 0.140 |
Why?
|
Stents | 2 | 2019 | 3177 | 0.140 |
Why?
|
Nitriles | 1 | 2022 | 971 | 0.140 |
Why?
|
Computer Simulation | 2 | 2024 | 6225 | 0.140 |
Why?
|
Oxygen Inhalation Therapy | 1 | 2020 | 411 | 0.140 |
Why?
|
Purinergic P2Y Receptor Antagonists | 1 | 2019 | 284 | 0.140 |
Why?
|
Heparin, Low-Molecular-Weight | 1 | 2019 | 344 | 0.140 |
Why?
|
Hepatitis B, Chronic | 2 | 2014 | 410 | 0.140 |
Why?
|
Positive-Pressure Respiration | 1 | 2021 | 638 | 0.140 |
Why?
|
Republic of Korea | 1 | 2019 | 576 | 0.140 |
Why?
|
Absorbable Implants | 1 | 2019 | 338 | 0.140 |
Why?
|
Male | 22 | 2024 | 360675 | 0.140 |
Why?
|
Uracil | 1 | 2018 | 207 | 0.140 |
Why?
|
Random Allocation | 1 | 2021 | 2393 | 0.130 |
Why?
|
Pravastatin | 1 | 2018 | 392 | 0.130 |
Why?
|
Radiotherapy, Intensity-Modulated | 1 | 2023 | 801 | 0.130 |
Why?
|
Aromatase Inhibitors | 1 | 2020 | 513 | 0.130 |
Why?
|
Monte Carlo Method | 2 | 2012 | 1257 | 0.130 |
Why?
|
Observation | 1 | 2017 | 310 | 0.130 |
Why?
|
Indazoles | 1 | 2017 | 304 | 0.130 |
Why?
|
Albuterol | 1 | 2016 | 211 | 0.130 |
Why?
|
Prognosis | 4 | 2019 | 29672 | 0.120 |
Why?
|
Adrenergic beta-Agonists | 1 | 2016 | 346 | 0.120 |
Why?
|
Probability | 1 | 2020 | 2478 | 0.120 |
Why?
|
Deoxycytidine | 1 | 2019 | 878 | 0.120 |
Why?
|
Independent Living | 1 | 2019 | 579 | 0.120 |
Why?
|
Metals | 1 | 2019 | 712 | 0.120 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2024 | 2270 | 0.120 |
Why?
|
Body Composition | 2 | 2019 | 2427 | 0.120 |
Why?
|
Gastrectomy | 1 | 2019 | 671 | 0.110 |
Why?
|
Rectum | 1 | 2019 | 891 | 0.110 |
Why?
|
Hematinics | 1 | 2016 | 282 | 0.110 |
Why?
|
Histocytochemistry | 1 | 2014 | 697 | 0.110 |
Why?
|
Rare Diseases | 1 | 2019 | 623 | 0.110 |
Why?
|
Transplantation, Autologous | 1 | 2018 | 2112 | 0.110 |
Why?
|
Spinal Curvatures | 1 | 2014 | 71 | 0.110 |
Why?
|
Administration, Inhalation | 1 | 2016 | 1157 | 0.110 |
Why?
|
Patient Admission | 1 | 2021 | 1365 | 0.110 |
Why?
|
Sentinel Lymph Node Biopsy | 1 | 2018 | 732 | 0.110 |
Why?
|
Estrogens | 1 | 2020 | 1521 | 0.110 |
Why?
|
Braces | 1 | 2014 | 139 | 0.110 |
Why?
|
Diphosphonates | 1 | 2018 | 636 | 0.110 |
Why?
|
Nursing Homes | 1 | 2021 | 1083 | 0.110 |
Why?
|
Esophagus | 1 | 2019 | 1033 | 0.100 |
Why?
|
Bronchodilator Agents | 1 | 2016 | 512 | 0.100 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2018 | 1089 | 0.100 |
Why?
|
Immunologic Factors | 1 | 2022 | 1589 | 0.100 |
Why?
|
Penicillamine | 1 | 2012 | 60 | 0.100 |
Why?
|
Incidence | 2 | 2022 | 21357 | 0.100 |
Why?
|
Erythropoietin | 1 | 2016 | 719 | 0.100 |
Why?
|
Sirolimus | 1 | 2019 | 1540 | 0.100 |
Why?
|
Polymers | 1 | 2019 | 1617 | 0.100 |
Why?
|
Combined Modality Therapy | 1 | 2023 | 8519 | 0.100 |
Why?
|
Anti-Asthmatic Agents | 1 | 2016 | 573 | 0.090 |
Why?
|
Primary Prevention | 1 | 2018 | 1185 | 0.090 |
Why?
|
Hemoglobins | 1 | 2016 | 1525 | 0.090 |
Why?
|
Ventricular Function, Left | 2 | 2023 | 3899 | 0.090 |
Why?
|
Biostatistics | 1 | 2012 | 164 | 0.090 |
Why?
|
Stem Cell Transplantation | 1 | 2018 | 1600 | 0.090 |
Why?
|
Survivors | 1 | 2020 | 2369 | 0.090 |
Why?
|
Elasticity Imaging Techniques | 1 | 2014 | 389 | 0.080 |
Why?
|
Aged | 12 | 2024 | 169266 | 0.080 |
Why?
|
Evidence-Based Medicine | 2 | 2019 | 3689 | 0.080 |
Why?
|
Nonlinear Dynamics | 1 | 2012 | 492 | 0.080 |
Why?
|
Natriuretic Agents | 1 | 2009 | 57 | 0.080 |
Why?
|
Sulfonamides | 1 | 2017 | 1977 | 0.070 |
Why?
|
Bone and Bones | 1 | 2018 | 2567 | 0.070 |
Why?
|
Heart Rate | 1 | 2019 | 4196 | 0.070 |
Why?
|
Anemia | 1 | 2016 | 1504 | 0.070 |
Why?
|
Pyridines | 1 | 2019 | 2872 | 0.070 |
Why?
|
Markov Chains | 1 | 2010 | 965 | 0.070 |
Why?
|
Recombinant Proteins | 1 | 2016 | 6507 | 0.070 |
Why?
|
Molecular Targeted Therapy | 1 | 2018 | 2813 | 0.070 |
Why?
|
Mortality | 1 | 2018 | 2896 | 0.070 |
Why?
|
Hepatitis C, Chronic | 1 | 2014 | 1027 | 0.070 |
Why?
|
Nucleosides | 1 | 2007 | 130 | 0.070 |
Why?
|
Diabetes Mellitus, Type 2 | 2 | 2021 | 12145 | 0.070 |
Why?
|
Carboxypeptidases | 1 | 2006 | 121 | 0.070 |
Why?
|
Neoplasm Proteins | 1 | 2018 | 3594 | 0.070 |
Why?
|
Meta-Analysis as Topic | 1 | 2011 | 1381 | 0.060 |
Why?
|
Waist-Hip Ratio | 1 | 2006 | 518 | 0.060 |
Why?
|
Pyrimidines | 1 | 2017 | 3026 | 0.060 |
Why?
|
Aortic Valve Stenosis | 1 | 2017 | 2018 | 0.060 |
Why?
|
Stroke Volume | 1 | 2019 | 5520 | 0.060 |
Why?
|
Naphthoquinones | 1 | 2004 | 58 | 0.060 |
Why?
|
Abdominal Fat | 1 | 2006 | 221 | 0.060 |
Why?
|
Reproducibility of Results | 1 | 2023 | 20120 | 0.060 |
Why?
|
Decision Making | 1 | 2018 | 3925 | 0.060 |
Why?
|
Liver Cirrhosis | 1 | 2014 | 1932 | 0.060 |
Why?
|
Exons | 1 | 2010 | 2380 | 0.060 |
Why?
|
Coronary Disease | 1 | 2018 | 5921 | 0.060 |
Why?
|
Thrombolytic Therapy | 1 | 2013 | 2055 | 0.060 |
Why?
|
Azithromycin | 1 | 2004 | 199 | 0.050 |
Why?
|
Creatinine | 1 | 2009 | 1897 | 0.050 |
Why?
|
Peritoneal Dialysis | 1 | 2024 | 159 | 0.050 |
Why?
|
Analysis of Variance | 1 | 2012 | 6224 | 0.050 |
Why?
|
Nevirapine | 1 | 2004 | 273 | 0.050 |
Why?
|
Child | 3 | 2023 | 80134 | 0.050 |
Why?
|
Gene Frequency | 1 | 2010 | 3603 | 0.050 |
Why?
|
Linkage Disequilibrium | 1 | 2007 | 1995 | 0.050 |
Why?
|
Adult | 9 | 2024 | 221083 | 0.050 |
Why?
|
Bayes Theorem | 1 | 2010 | 2327 | 0.050 |
Why?
|
Polymorphism, Single Nucleotide | 3 | 2007 | 15915 | 0.050 |
Why?
|
Algorithms | 4 | 2021 | 14023 | 0.050 |
Why?
|
Protein Kinase Inhibitors | 1 | 2018 | 5662 | 0.050 |
Why?
|
Loss of Heterozygosity | 1 | 2004 | 663 | 0.050 |
Why?
|
AIDS-Related Opportunistic Infections | 1 | 2004 | 662 | 0.050 |
Why?
|
Hospitalization | 1 | 2020 | 10712 | 0.040 |
Why?
|
Prednisolone | 1 | 2021 | 324 | 0.040 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2009 | 1725 | 0.040 |
Why?
|
Quality of Life | 2 | 2024 | 13362 | 0.040 |
Why?
|
HIV Infections | 3 | 2018 | 17349 | 0.040 |
Why?
|
Follow-Up Studies | 2 | 2019 | 39121 | 0.040 |
Why?
|
Cholinesterase Inhibitors | 1 | 2021 | 241 | 0.040 |
Why?
|
Iceland | 1 | 2019 | 184 | 0.040 |
Why?
|
Statistics, Nonparametric | 1 | 2024 | 2855 | 0.040 |
Why?
|
Oligonucleotide Array Sequence Analysis | 2 | 2004 | 3776 | 0.040 |
Why?
|
Middle Aged | 8 | 2024 | 220835 | 0.040 |
Why?
|
Brain | 1 | 2024 | 27097 | 0.040 |
Why?
|
User-Computer Interface | 1 | 2004 | 1395 | 0.040 |
Why?
|
Alzheimer Disease | 1 | 2019 | 8601 | 0.040 |
Why?
|
Prospective Studies | 2 | 2019 | 54419 | 0.040 |
Why?
|
Genetic Variation | 2 | 2010 | 6565 | 0.030 |
Why?
|
Prednisone | 1 | 2021 | 1565 | 0.030 |
Why?
|
Pre-Eclampsia | 1 | 2006 | 1231 | 0.030 |
Why?
|
Aged, 80 and over | 4 | 2024 | 58946 | 0.030 |
Why?
|
CD4 Lymphocyte Count | 2 | 2018 | 2569 | 0.030 |
Why?
|
Patient Dropouts | 1 | 2019 | 411 | 0.030 |
Why?
|
Bacterial Infections | 1 | 2004 | 1390 | 0.030 |
Why?
|
Obesity | 1 | 2019 | 12937 | 0.030 |
Why?
|
Benzhydryl Compounds | 1 | 2023 | 917 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 1 | 2019 | 20600 | 0.030 |
Why?
|
Treatment Failure | 1 | 2021 | 2643 | 0.030 |
Why?
|
Antiviral Agents | 1 | 2007 | 3048 | 0.030 |
Why?
|
Antiretroviral Therapy, Highly Active | 2 | 2018 | 1895 | 0.030 |
Why?
|
Infusions, Intravenous | 1 | 2019 | 2217 | 0.030 |
Why?
|
Models, Genetic | 3 | 2010 | 3430 | 0.030 |
Why?
|
Sequence Analysis, DNA | 1 | 2004 | 4739 | 0.030 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2004 | 2150 | 0.020 |
Why?
|
Endothelium, Vascular | 1 | 2024 | 4421 | 0.020 |
Why?
|
Gene Expression Profiling | 2 | 2004 | 9416 | 0.020 |
Why?
|
Gene Expression | 2 | 2018 | 7567 | 0.020 |
Why?
|
Socioeconomic Factors | 1 | 2024 | 7804 | 0.020 |
Why?
|
Pilot Projects | 1 | 2024 | 8639 | 0.020 |
Why?
|
Genetic Markers | 2 | 2007 | 2599 | 0.020 |
Why?
|
Activities of Daily Living | 1 | 2019 | 2420 | 0.020 |
Why?
|
Viral Load | 1 | 2018 | 3328 | 0.020 |
Why?
|
Anti-HIV Agents | 1 | 2004 | 4526 | 0.020 |
Why?
|
Prevalence | 1 | 2024 | 15717 | 0.020 |
Why?
|
ROC Curve | 1 | 2014 | 3582 | 0.020 |
Why?
|
Hepatitis B e Antigens | 1 | 2007 | 133 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2019 | 10755 | 0.020 |
Why?
|
Angiotensinogen | 1 | 2006 | 160 | 0.020 |
Why?
|
Electrocardiography | 1 | 2019 | 6385 | 0.020 |
Why?
|
Guanine | 1 | 2007 | 278 | 0.020 |
Why?
|
Chromosome Mapping | 2 | 2004 | 4612 | 0.020 |
Why?
|
Lamivudine | 1 | 2007 | 366 | 0.020 |
Why?
|
Genetics, Population | 1 | 2010 | 935 | 0.020 |
Why?
|
Rural Health | 1 | 2006 | 296 | 0.020 |
Why?
|
Atovaquone | 1 | 2004 | 56 | 0.020 |
Why?
|
Retrospective Studies | 2 | 2024 | 80673 | 0.010 |
Why?
|
Nelfinavir | 1 | 2004 | 68 | 0.010 |
Why?
|
Peptidyl-Dipeptidase A | 1 | 2006 | 328 | 0.010 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2007 | 628 | 0.010 |
Why?
|
Pneumonia, Pneumocystis | 1 | 2004 | 242 | 0.010 |
Why?
|
Renal Insufficiency | 1 | 2009 | 808 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2024 | 26068 | 0.010 |
Why?
|
Biopsy | 1 | 2014 | 6781 | 0.010 |
Why?
|
Interferon-alpha | 1 | 2007 | 907 | 0.010 |
Why?
|
Liver Failure, Acute | 1 | 2004 | 181 | 0.010 |
Why?
|
Chromosomes, Human, Pair 5 | 1 | 2004 | 386 | 0.010 |
Why?
|
Chromosomes, Human, Pair 16 | 1 | 2004 | 343 | 0.010 |
Why?
|
United States | 2 | 2024 | 72337 | 0.010 |
Why?
|
Disease Progression | 1 | 2019 | 13506 | 0.010 |
Why?
|
Cohort Studies | 1 | 2024 | 41486 | 0.010 |
Why?
|
Renin-Angiotensin System | 1 | 2006 | 735 | 0.010 |
Why?
|
Stevens-Johnson Syndrome | 1 | 2004 | 246 | 0.010 |
Why?
|
Cognition | 1 | 2019 | 6987 | 0.010 |
Why?
|
Adenine | 1 | 2007 | 986 | 0.010 |
Why?
|
HIV-1 | 1 | 2018 | 6851 | 0.010 |
Why?
|
Absorptiometry, Photon | 1 | 2006 | 1738 | 0.010 |
Why?
|
China | 1 | 2006 | 2374 | 0.010 |
Why?
|
Sequence Alignment | 1 | 2004 | 2175 | 0.010 |
Why?
|
Safety | 1 | 2004 | 1151 | 0.010 |
Why?
|
Case-Control Studies | 2 | 2007 | 22157 | 0.010 |
Why?
|
Administration, Oral | 1 | 2007 | 4014 | 0.010 |
Why?
|
DNA, Neoplasm | 1 | 2004 | 1743 | 0.010 |
Why?
|
Cluster Analysis | 1 | 2004 | 2706 | 0.010 |
Why?
|
Health Surveys | 1 | 2006 | 4036 | 0.010 |
Why?
|
Rural Population | 1 | 2006 | 2277 | 0.010 |
Why?
|
Drug Therapy, Combination | 1 | 2004 | 6305 | 0.010 |
Why?
|
Infant, Newborn | 2 | 2004 | 26187 | 0.010 |
Why?
|
Odds Ratio | 1 | 2006 | 9648 | 0.010 |
Why?
|
Kidney | 1 | 2009 | 7034 | 0.010 |
Why?
|
Pregnancy | 2 | 2006 | 29872 | 0.010 |
Why?
|
Boston | 1 | 2006 | 9324 | 0.010 |
Why?
|
Sex Factors | 1 | 2006 | 10552 | 0.010 |
Why?
|
Risk Factors | 1 | 2019 | 74219 | 0.010 |
Why?
|
Genotype | 1 | 2006 | 12983 | 0.010 |
Why?
|
Chronic Disease | 1 | 2006 | 9317 | 0.010 |
Why?
|
Genetic Testing | 1 | 2004 | 3536 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2010 | 12670 | 0.010 |
Why?
|
Software | 1 | 2004 | 4433 | 0.010 |
Why?
|
Age Factors | 1 | 2006 | 18385 | 0.010 |
Why?
|
Body Mass Index | 1 | 2006 | 12951 | 0.000 |
Why?
|
Phenotype | 1 | 2006 | 16572 | 0.000 |
Why?
|
Infant | 1 | 2004 | 36164 | 0.000 |
Why?
|
Child, Preschool | 1 | 2004 | 42217 | 0.000 |
Why?
|
Adolescent | 1 | 2004 | 88271 | 0.000 |
Why?
|